Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

UBS Financial Upgrades Amgen

UBS Financial upgrades biotech company Amgen (AMGN) to buy from neutral.

Analyst David Molowa says he thinks investors have viewed Amgen as a decelerating growth company fraught with risks, even as growth exceeded expectations.

He believes the shift in investor focus from threats to opportunities for future growth will result in revaluation of shares, similarly to other diversified health care companies. He sees a plethora of growth opportunities.

Molowa says Medicare reimbursement changes should have minimal impact in 2006. He raises his $2.90 2005 earnings per share estimate to $2.91, and his $3.32 2006 earnings per share to $3.36. He raises his $63 price target to $80.

blog comments powered by Disqus